Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 28

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 28
---
 preserve the listing of our Depositary Shares on The NASDAQ Capital Market, but these measures and any appeal may not
be successful. If our Depositary Shares are delisted by NASDAQ, our Depositary Shares may be eligible to trade on an over-the-counter
quotation system, where an investor may find it more difficult to sell our Depositary Shares or obtain accurate quotations as to the market
value of our Depositary Shares. We cannot ensure that our Depositary Shares, if delisted from The NASDAQ Capital Market, will be listed
on any national securities exchange or quoted on an over-the counter quotation system.

In
the event we are delisted from The NASDAQ Capital Market, the only established trading market for our Depositary Shares would be eliminated,
and we would be forced to list our shares on the OTC Markets or another quotation medium, depending on our ability to meet the specific
listing requirements of those quotation systems. As a result, an investor would likely find it more difficult to trade or obtain accurate
price quotations for our Depositary Shares. Delisting would likely also reduce the visibility, liquidity, and value of our Depositary
Shares, reduce institutional investor interest in our company, and may increase the volatility of our Depositary Shares. Delisting could
also cause a loss of confidence of potential industry partners, lenders, and employees, which could further harm our business and our
future prospects.

Unless
our Depositary Shares are listed on a national securities exchange, such as NASDAQ, our Depositary Shares will also likely be subject
to the regulations and restrictions regarding trading in “penny stocks,” which are those securities trading for less than
$5.00 per share, and that are not otherwise exempted from the definition of a penny stock under other exemptions provided for in the applicable
regulations. These penny stock requirements and regulations could severely limit the liquidity of our Depositary Shares in the secondary
market because fewer brokers or dealers would be likely to be willing to undertake related compliance activities to trade in our Depositary
Shares. If our Depositary Shares are not listed on a national securities exchange, the rules and restrictions regarding penny stock transactions
may limit an investor’s ability to sell to a third-party and our trading activity in the secondary market may be reduced. Delisting
from The NASDAQ Capital Market would also likely limit the range and attractiveness of strategic alternatives that we are able to consider,
adversely affect our ability to raise additional capital through the public or private sale of equity securities, significantly